JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, D. J.
Right arrow Articles by Angel, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, D. J.
Right arrow Articles by Angel, I.

Vol. 282, Issue 1, 228-235, 1997

Comparative Alpha-1 Adrenoceptor Subtype Selectivity and Functional Uroselectivity of Alpha-1 Adrenoceptor Antagonists

D. J. Martin, P. Lluel, E. Guillot, A. Coste, D. Jammes and I. Angel

Synthélabo Recherche, Department of Internal Medicine, 10 rue des Carrières, 92504 Rueil-Malmaison, France

We investigated the relevance of selectivity for a given alpha-1-adrenoceptor subtype for in vivo uroselectivity of several alpha-1-adrenoceptor antagonists (alfuzosin, doxazosin, prazosin, tamsulosin, terazosin and 5-Me-urapidil). Comparison of the affinities of these alpha-1-adrenoceptor antagonists at the cloned alpha-1a, alpha-1b and alpha-1d-adrenoceptor subtypes revealed that tamsulosin and 5-Me-urapidil showed selectivity for the alpha-1a subtype. No significant correlations were found between the affinities for alpha-1b or alpha-1d-adrenoceptors and the pKB values obtained against phenylephrine-induced contraction of the rabbit prostate in vitro. In contrast, the antagonist potencies in rabbit prostate were correlated (r = 0.89, P < .05) with the pKi values for the alpha-1a-adrenoceptor subtype. However, the pKB values were consistently smaller (by 0.6 to 1.9 log unit) than the pKi values for the alpha-1a-adrenoceptor subtype, a result that suggests that the alpha-1-adrenoceptor mediating urethral contractions does not have all the characteristics of the alpha-1a-adrenoceptor. The simultaneous measurement of urethral and arterial pressures in the same conscious male rat allows evaluation of the functional uroselectivity of these antagonists based on their respective effects on both pressures. Dose ranges were selected according to effects on urethral pressure and most antagonists were found effective within the 3 to 100 µg/kg i.v. range. Alfuzosin markedly decreased urethral pressure and either did not decrease blood pressure (10-30 µg/kg) or slightly decreased it at the highest dose tested (100 µg/kg). Doxazosin did not produce sustained reductions in urethral pressure until a dose of 30 µg/kg. Blood pressure was not reduced until 100 µg/kg. Prazosin reduced urethral pressure and blood pressure within the same dose-range whereas terazosin did not decrease urethral pressure at doses that significantly decreased blood pressure (30 and 100 µg/kg). 5-Me-urapidil, an alpha-1a-selective compound did not significantly modify urethral and blood pressure whereas tamsulosin, another alpha-1a-selective compound reduced urethral pressure and blood pressure within the same dose range. In conclusion, in the conscious male rat the functional uroselectivity is not correlated with a selective affinity for the alpha-1a-adrenoceptor subtype.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. A. Hancock, S. A. Buckner, M. E. Brune, T. A. Esbenshade, L. M. Ireland, S. Katwala, I. Milicic, M. D. Meyer, J. F. Kerwin Jr., and M. Williams
Preclinical Pharmacology of Fiduxosin, a Novel alpha 1-Adrenoceptor Antagonist with Uroselective Properties
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 478 - 486.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Yamada, T. Okura, R. Kimura, Y. Deguchi, Y. Suzuki, T. Kobayashi, and K. Aisaka
Disposition and alpha 1-Adrenoceptor Binding Characteristics of JTH-601 and Its Metabolites in Rat Tissues
Drug Metab. Dispos., April 13, 2001; 28(12): 1487 - 1492.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Yamada, T. Okura, and R. Kimura
In Vivo Demonstration of {alpha}1A-Adrenoceptor Subtype Selectivity of KMD-3213 in Rat Tissues
J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 160 - 167.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
V. L. Pulito, X. Li, S. S. Varga, L. S. Mulcahy, K. S. Clark, S. A. Halbert, A. B. Reitz, W. V. Murray, and L. K. Jolliffe
An Investigation of the Uroselective Properties of Four Novel alpha 1a-Adrenergic Receptor Subtype-Selective Antagonists
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 224 - 229.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Fukuta, Y. Fukuda, R. Higashino, K. Yoshida, M. Ogishima, H. Tamaki, and M. Takei
Z-350, A Novel Compound with alpha 1-Adrenoceptor Antagonistic and Steroid 5alpha -Reductase Inhibitory Actions: Pharmacological Properties In Vivo
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1013 - 1018.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Yamada, T. Ohkura, Y. Deguchi, and R. Kimura
In Vivo Measurement by [3H]Tamsulosin of alpha 1 Adrenoceptors in Rat Tissues in Relation to the Pharmacokinetics
J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1575 - 1583.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.